Valuation: Theravance Inc

Market Cap 1.6B 1.4B 1.29B 1.19B 2.24B 154B 2.29B 15.44B 6.07B 75.58B 6.02B 5.89B 260B P/E 2026 *
6.5x
P/E 2027 * 9.49x
Enterprise Value 1.09B 951M 878M 809M 1.52B 105B 1.56B 10.49B 4.13B 51.33B 4.09B 4B 177B EV / Sales 2026 *
2.47x
EV / Sales 2027 * 1.8x
Free-Float
99.01%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 42 19/05/2020
Director of Finance/CFO 60 20/08/2023
Investor Relations Contact - 31/08/2025
Director TitleAgeSince
Director/Board Member 75 11/02/2018
Director/Board Member 66 11/02/2018
Director/Board Member 42 18/05/2025
Change 5-day change 1-year change 3-year change Capi.($)
+0.85%-0.80%+54.84%+163.70% 1,051B
+1.23%-1.53%+55.26%+59.07% 609B
+0.04%+2.58%+32.96%+88.75% 450B
+0.78%-0.71%+30.04%+24.61% 330B
+1.41%+0.58%+33.92%+47.20% 284B
-0.27%-1.87%+22.13%+23.47% 263B
-1.76%+2.37%-22.19%-38.45% 223B
-1.42%+0.80%+22.81%+60.77% 198B
-1.48%+3.43%+23.42%+73.31% 167B
Average -0.12%+0.54%+28.13%+55.82% 397.23B
Weighted average by Cap. +0.22%+0.02%+37.75%+81.49%

Financials

2026 *2027 *
Net sales 441M 385M 355M 327M 617M 42.43B 631M 4.25B 1.67B 20.78B 1.65B 1.62B 71.53B 486M 425M 392M 361M 681M 46.81B 696M 4.68B 1.84B 22.93B 1.83B 1.79B 78.92B
Net income 286M 250M 231M 213M 401M 27.54B 409M 2.76B 1.08B 13.49B 1.07B 1.05B 46.43B 185M 162M 149M 138M 259M 17.83B 265M 1.78B 702M 8.73B 695M 680M 30.06B
Net Debt -514M -449M -415M -382M -720M -49.51B -736M -4.95B -1.95B -24.25B -1.93B -1.89B -83.47B -728M -637M -587M -541M -1.02B -70.15B -1.04B -7.02B -2.76B -34.36B -2.74B -2.68B -118B
Logo Theravance Inc
Innoviva, Inc. is a diversified holding company with a portfolio of royalties and other healthcare assets. The Company's royalty portfolio consists of respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, the Company is entitled to receive royalties from GSK on sales of RELVAR/BREO, ELLIPTA. The Company's products include GIAPREZA (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock, and XERAVA (eravacycline) approved for the treatment of complicated intra-abdominal infections in adults. The third product, XACDURO (formerly known as sulbactam-durlobactam or SUL-DUR), is approved for the treatment of hospital-acquired and ventilator-associated pneumonias caused by Acinetobacter in adults. The development pipeline includes zoliflodacin, an investigational treatment for uncomplicated gonorrhea is in Phase III clinical trial.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-